Jagsonpal Pharmaceuticals Limited has filed a regulatory disclosure with BSE Ltd and National Stock Exchange of India Ltd regarding the completion of an equity acquisition.
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company refers to its previous communications dated June 29, 2026 and July 7, 2026, in which it had informed the exchanges about a proposed acquisition of an 85% equity stake in Aequitas Healthcare Private Limited ("Aequitas").
Further to these prior disclosures, the company announces that it has completed the acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited. This completed stake is against the originally proposed acquisition of 85%.
The company has requested the stock exchanges to take this completion of the acquisition on record.
The disclosure is digitally signed by Pratham Rawal, Company Secretary & Compliance Officer, on July 8, 2026, at 16:46:24 IST.
#JagsonpalPharmaceuticals #AequitasHealthcare #Regulation30 #SEBIDisclosure #M&A